Trial Profile

A Phase I/II First-In-Human Clinical Trial to Evaluate the Safety, Tolerability and Anti-Tumor Activity of IMA402, a Bispecific TCER Targeting PRAME, in Patients With Recurrent and/or Refractory Solid Tumors

Status: Recruiting

Phase of Trial: Phase I/II

Latest Information Update: 22 Jul 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs IMA 402 (Primary)
Indications Gynaecological cancer; Lung cancer; Malignant melanoma; Ovarian cancer; Skin cancer; Solid tumours; Synovial sarcoma; Uterine cancer; Uveal melanoma
Focus Adverse reactions; First in man; Proof of concept; Therapeutic Use
Sponsors Immatics N.V.

17 Jul 2026 According to an Immatics media release, the data from the trial will be presented at the at the European Society for Medical Oncology (ESMO) Congress 2026.
01 Jul 2026 Planned number of patients changed from 155 to 400.
12 May 2026 According to an Immatics media release, the Company is in the process of opening additional Phase 1b cohorts in mid-2026 across both earlier and later treatment lines.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com